<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522872</url>
  </required_header>
  <id_info>
    <org_study_id>TH-CR-408</org_study_id>
    <nct_id>NCT01522872</nct_id>
  </id_info>
  <brief_title>Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and
      dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory
      multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the initial study of TH-302 in subjects with relapsed/refractory multiple myeloma. It
      is an open-label dose-escalation study to determine the DLTs, MTD, safety and preliminary
      efficacy of TH-302 and dexamethasone with a Simon two-stage expansion at the MTD. The study
      will also investigate the DLTs, MTD, safety and preliminary efficacy of TH-302, dexamethasone
      and bortezomib; and the DLTs, MTD, safety and preliminary efficacy of TH-302, dexamethasone
      and pomalidomide. As such, the study is separated into four parts. Treatment will be
      administered until disease progression or unacceptable toxicity, or 12 cycles (Arm A, Arm B
      and Arm C) or 9 cycles (Arm D) have been completed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of adverse events(AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events(AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of TH-302 and dexamethasone with or without bortezomib or pomalidomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>recommended Phase 2 dose for TH-302 and dexamethasone with or without bortezomib or pomalidomide</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between hypoxia within the bone marrow of subjects with relapsed/refractory multiple myeloma and response to TH-302 and dexamethasone with or without bortezomib or pomalidomide using markers of hypoxia</measure>
    <time_frame>Up to 12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of TH-302 and bortezomib</measure>
    <time_frame>Cycle 1 Day 1 predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Monotherapy TH-302 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 and Dexamethasone Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Pomalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302</intervention_name>
    <arm_group_label>Monotherapy TH-302 Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 and Dexamethasone</intervention_name>
    <arm_group_label>TH-302 and Dexamethasone Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib</intervention_name>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Bortezomib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide</intervention_name>
    <arm_group_label>TH-302 Dose Escalation and Dexamethasone with Pomalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age.

          2. Ability to understand the purposes and risks of the study and has signed a written
             informed consent form approved by the investigator's IRB/Ethics Committee.

          3. Relapsed/refractory multiple myeloma for which no standard therapy options are
             anticipated to result in a durable remission.

          4. Receipt of at least two prior therapies as indicated by protocol

          5. Subjects with measurable disease

          6. ECOG performance status of less than or equal to 2

          7. Acceptable liver function

          8. Acceptable renal function

          9. Acceptable hematologic status

         10. For Part A, B, C subjects: Women of childbearing potential must have a negative serum
             pregnancy test and women and men subjects must agree to use effective means of
             contraception with their partner as indicated by protocol For Part D subjects: a
             negative serum pregnancy test is required within 10- 14 days prior to initiating with
             pomalidomide, AND a negative serum pregnancy test within 24 hours of starting
             pomalidomide and must either commit to continued abstinence from heterosexual
             intercourse or begin two acceptable methods of birth control at least 28 days before
             she starts taking pomalidomide.

             Women of childbearing potential must enroll into and follow all requirements of the
             POMALYST REMS program, which includes adhering to the scheduled pregnancy testing.

             Men must agree to use a latex or synthetic condom during sexual contact with women of
             child bearing potential even if they have had a vasectomy.

             All subjects must be counseled at a minimum of every 28 days about pregnancy
             precautions and risks of fetal exposure, or when a female patient misses her period or
             if there is any abnormality in her menstrual bleeding.

         11. Subjects must adhere to the study visit schedule and other protocol requirements and
             receive outpatient therapy and laboratory monitoring at the institute that administers
             the study drug.

        Exclusion Criteria

        Subjects who meet any of the following exclusion criteria are not eligible to be enrolled
        in this study:

          1. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy
             and skin changes.)

          2. Waldenstrom's macroglobulinemia

          3. Localized radiation therapy to only measurable disease site(s) within 2 weeks of
             treatment

          4. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial
             infarction within 6 months prior to Day 1, or unstable arrhythmia

          5. Significant neuropathy (Grade 3 or 4, or Grade 2 with pain) at the time of enrollment
             or within 14 days before enrollment

          6. Symptomatic brain metastases (unless previously treated and well controlled for a
             period of â‰¥ 3 months)

          7. Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the
             investigator any physiological state leading to hypoxemia

          8. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without
             complete recovery

          9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy within 14 days prior to the first dose

         10. Previously treated malignancies, except for adequately treated non-melanoma skin
             cancer (basal cell or squamous cell), in situ cancer, or other cancer from which the
             subject has been disease-free for at least 5 years

         11. Subjects who participated in an investigational drug or device study within 2 weeks
             prior to study entry

         12. Known or suspected active infection with HIV, hepatitis A, hepatitis B, or hepatitis C

         13. Subjects who have exhibited allergic reactions to a similar structural compound,
             biological agent, or formulation similar to TH-302, bortezomib (for subjects enrolled
             in Part C only), pomalidomide (Part D), dexamethasone or pimonidazole

         14. Females who are pregnant or breast-feeding

         15. Concomitant psychiatric disease or medical condition that could interfere with the
             conduct of the study, or that would, in the opinion of the investigator, pose an
             unacceptable risk to the subject in this study

         16. Unwillingness or inability to comply with the study protocol for any reason

         17. Previous cytotoxic therapies for multiple myeloma within 3 weeks prior to study entry
             (2 weeks for biologic, novel therapy or corticosteroids)

         18. Subjects who have been on hormone replacement less than 2 months (subjects on hormone
             replacement for at least 2 months will not be excluded provided the HRT regimen
             remains unchanged during the conduct of the study).

         19. Prior peripheral stem cell transplant within 12 weeks of the start of study

         20. Epilepsy or other convulsive disorder requiring active management

         21. Prior therapy with a pomalidomide-containing regimen

         22. Subjects on strong inducers or strong inhibitors of cytochrome P450 CYP3A4 or CYP1A2

         23. Any other medical condition that in opinion of investigator would place patient at
             increased risk for toxicity during pomalidomide treatment (i.e. history of recurrent
             or serious thromboembolic events)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Southaven</city>
        <state>Mississippi</state>
        <zip>38671</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Hudson</city>
        <state>New York</state>
        <zip>12534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TH-302</keyword>
  <keyword>Relapsed/Refractory Multiple Myeloma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Phase 1/2</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Evofosfamide</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>Pimonidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Phosphoramide Mustards</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

